NASDAQ: ALXN

Alexion Launches 2020 CSR Report Written From Employee Perspective

Article

Alexion, a global biopharmaceutical company (NASDAQ: ALXN), is committed to all the communities we engage with including patients, caregivers and their families; our valued employees and future talent; our neighbors around the world; investors; patient organizations; suppliers; business partners and others. This collective passion comes to life in our 2020 Corporate Social Responsibility (CSR) report, Dear Communities, which is written from the first-person perspective of Alexion employees.

Alexion CEO Ludwig Hantson embodies the personal tone in his opening words:

Alexion Recognized on Newsweek's America's Most Responsible Companies 2021 List

Article

Alexion has been named to Newsweek Magazine's America's Most Responsible Companies 2021 list, which recognizes top-performing companies that are creating value for their stakeholder communities and publicly reporting their progress. In partnership with Statista Inc., Newsweek identified the top 400 most responsible companies from a pool of over 2,000 organizations across 14 industries, based on publicly available information as well as an independent study of 7,500 U.S. residents.

Celebrating the Alexion Charitable Foundation One Year Anniversary

Article

The Alexion Charitable Foundation (ACF), launched by Alexion Pharmaceuticals, Inc. in February 2020, marks its first anniversary this month in tandem with the celebration of Rare Disease Day. The Foundation was established with the mission to offer promise and cultivate a sense of belonging, particularly for people affected by a rare disease. This article marks the major milestones made toward that purpose in year one and highlights the work of several unique grantees funded by the Foundation.

Rare Answers™: A System to Improve Patient Outcomes

Article

At Alexion, Corporate Social Responsibility (CSR) is an inherent part of everything we do and supports our mission to transform the lives of people affected by rare diseases and devastating conditions. In addition to developing and delivering life-changing medicines, this mission drives us to seek opportunities to advance innovative solutions to system-wide challenges faced by rare disease patients, such as the “diagnostic odyssey.”

Health Equity at Alexion

Article

As a leader in rare disease, it is our responsibility to lead critical conversations with stakeholders and other members of the rare disease community. Health equity is one of those conversations.

Alexion Highlights Brighter Futures in 2019 CSR Report

Article

March 30, 2020 - Alexion Pharmaceuticals (NASDAQ: ALXN), a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines, releases its inaugural corporate social responsibility (CSR) report, Brighter Futures.

Subscribe to NASDAQ: ALXN